You are here: Industry Insights > Market News > Nearly 2.219b COVID-19 vaccine doses administered on Chinese mainland

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Nearly 2.219b COVID-19 vaccine doses administered on Chinese mainland

NMPAOctober 13, 2021

Tag: COVID-19 , Chinese mainland , National Health Commission

Favorites

BEIJING -- Nearly 2.219 billion doses of COVID-19 vaccine had been administered on the Chinese mainland as of Friday, data from the National Health Commission showed on Oct 9.

Previous:Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins

Next:NeoPlex (TM) HPV29 Detection, a new molecular detection kit from Genematrix, acquires European CE-IVD certification

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

Selection of Commercial Models for Innovative Drugs

PharmaSourcesMay 21, 2024

Nearly 2.219b COVID-19 vaccine doses administered on Chinese mainland | Pharmasources.com

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

Nearly 2.219b COVID-19 vaccine doses administered on Chinese mainland

Related News

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Selection of Commercial Models for Innovative Drugs

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

You may like